Therefore, our study not only uncovers the relevance of NOTCH1 in AML but also provides a convincing basis to further escalate the therapeutic targeting of NOTCH1 and combined treatment strategies in our model and clinical studies in the future to combat master oncogenic drivers in MLLr AML. The gene discussed is NOTCH1; the disease is acute myeloid leukemia.